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Introduction: In 2015, the US Alzheimer’s Disease Centers (ADC)
implemented Version 3 of the Uniform Data Set (UDS). This paper
describes the history of Version 3 development and the UDS data
that are freely available to researchers.
Methods: UDS Version 3 was developed after years of coordination
between the National Institute on Aging-appointed Clinical Task
Force (CTF), clinicians from ∼30 ADCs, and the National
Alzheimer’s Coordinating Center (NACC). The CTF recognized

the need for updates to align with the state of the science in
dementia research, while being ﬂexible to the diverse needs and
diseases studied at the ADCs. Version 3 also developed a nonproprietary neuropsychological battery.
Results: This paper focuses on the substantial Version 3 changes to
the UDS forms related to clinical diagnosis and characterization of
clinical symptoms to match updated consensus-based diagnostic
criteria. Between March 2015 and March 2018, 4820 participants
were enrolled using UDS Version 3. Longitudinal data were
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available for 25,337 of the 37,568 total participants using all UDS
versions.
Discussion: The results from utilization of the UDS highlight the
possibility for numerous research institutions to successfully collaborate, produce, and use standardized data collection instruments for
over a decade.
Key Words: Alzheimer disease center, National Alzheimer’s Coordinating Center, Alzheimer disease, Lewy body disease, frontotemporal degeneration, MCI

(Alzheimer Dis Assoc Disord 2018;32:351–358)

I

n 1984, the US National Institute on Aging (NIA) of the
National Institutes of Health inaugurated the Alzheimer’s
Disease Centers (ADC) program, aimed at providing a
comprehensive approach to research on Alzheimer disease
(AD) and related disorders. Through their research, ADCs
are expected to aid in early detection, diagnosis, treatment,
and prevention of neurodegenerative disease. As part of the
ADC program, Centers’ data must be collected in a
standardized manner, but also in a way that allows individual Centers to maintain their unique research foci and
strategies. To date, the NIA has funded 39 past and present
ADCs that are located at medical institutions across the
United States, and the ADC program has continually
evolved to adapt to the state of the science.
At the start, ADCs collected data primarily retrospectively (eg, chart review) as part of the Minimum Data
Set (MDS), with data collection coordinated by the
National Alzheimer’s Coordinating Center (NACC) starting
in 1999. The MDS was a cross-sectional data set consisting
of limited data on demographics, clinical diagnoses, and
neuropathologic ﬁndings (when available). It largely served
as a library/cataloging service.
In 2005, ADCs began collecting longitudinal demographic, clinical, neuropsychological, and diagnostic data
on participants using Version 1 of the Uniform Data Set
(UDS). Details on the data collected and the process of
developing UDS Version 1 can be found elsewhere.1 UDS
Version 2 was implemented in 2008, resulting in a mostly
minor update to the original data collection instruments
such as adding a few new questions to the forms, restructuring of form logic (eg, skip patterns), and adding a few
neuropsychological test elements [eg, Mini Mental State
Exam (MMSE)2 pentagon item score].
In contrast, numerous important changes were made
with the implementation of UDS Version 3, including the
addition of the Form C2 neuropsychological test battery.3
The aims of this paper are to describe the history of development and implementation of UDS Version 3, the UDS
data that are currently available, and the types of studies
that can be conducted using this important resource. Previous published papers focus on the UDS Version 3 neuropsychological test battery only.3,4 This paper describes the
overall development of the UDS Version 3, which consists
of a number of instruments beyond the neuropsychological
test battery; the particular clinical data it collects; and the
supplementary data that are available.

METHODS
The original impetus for the development and adoption
of UDS Version 3 was the desire for an updated neuropsychological test battery, details of which have been
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thoroughly described elsewhere.3 Some of the beneﬁts of the
updated test battery are that it is nonproprietary and that it
includes a new episodic memory test to reduce practice
effects observed in repeatedly using the prior version.
A primary goal in the development of the UDS Version 3
neuropsychological battery was a set of nonproprietary tests
that would allow sharing and comparison across various
studies. Thus, some of the chosen tests were initially missing
norms with which to reference until sufﬁcient sample size
allowed UDS Version 3 norms to be posted on the NACC
website and to be published in 2018.3 In addition, the new
test battery now captures visuospatial and nonverbal
memory function, domains not previously tested in UDS
Versions 1 and 2. The careful review, evaluation, and
implementation of the new battery took a number of years
and was overseen by the Neuropsychology Work Group, a
subcommittee of the ADCs’ Clinical Task Force (CTF).
Before implementation, the ADCs pilot tested the new
battery (ie, the Crosswalk Study4), which allowed the Neuropsychology Work Group to assess if new and old tests
capturing the same domains could be equated and used in
longitudinal analyses. Results from the crosswalk study
indicated that Version 3 neuropsychological tests were well
correlated with Version 2 tests (ρ = 0.68 to 0.78).4 The
crosswalk study also suggested methods to convert scores on
the Version 3 tests to comparable scores from the Version 2
battery. These conversion factors allow for comparison of
all available initial visit test scores among individuals,
whether they received UDS Version 2 or 3 at baseline, and
for longitudinal comparison of test scores for participants
who received both Version 2 and subsequently Version 3
tests during follow-up.
Along with the neuropsychological test changes, a number of other substantive edits were made to the forms in Version 3. These changes were instituted by the CTF in order to
streamline the forms and adapt to the latest diagnostic criteria,
including biomarker measures. Moreover, new questions were
added to assess clinical characteristics of related neurodegenerative disorders [eg, frontotemporal lobar degeneration
(FTLD) mutations, repeated traumatic brain injuries (TBIs)],
reﬂecting the ADC program’s expanding and diversifying
research priorities. Decisions were made by the entire CTF,
wherein consensus if not unanimity almost always was achieved whenever possible. The CTF Chair was tasked with
resolving any impasses that arose.
With the goal of streamlining the UDS, the CTF
worked with the NACC to review UDS Version 2, form by
form, identifying questions that were redundant across
forms and opportunities to increase the clarity of the
questions and/or instructions. The decision to eliminate
entire forms or large numbers of items was made by the
CTF if items were both infrequently used by researchers
and deemed no longer necessary to the basic clinical
work-up.
After a comprehensive review of the forms, few data
elements from Version 2 were eliminated due to redundancy,
and a few wording and coding changes were suggested to
clarify data elements. In the end, the major changes
(Table 1) included modiﬁcations to the clinical diagnosis
form (Form D1), the removal of the Hachinski Ischemic
Score (Form B2) [given the increased use of magnetic
resonance imaging (MRI) to document ischemic burden]
and the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS;
Form B3), and the addition of summary neurological
examination ﬁndings (Form B8) and clinician-assessed
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TABLE 1. Major Changes Implemented With Version 3 of the Uniform Data Set Initial Visit Packet

Form
A1: Subject Demographics
A2: Co-participant Demographics
A3: Subject Family History
A4: Subject Medications
A5: Subject Health History*

B1:
B2:
B3:
B4:
B5:
B6:
B7:
B8:

Evaluation Form—Physical
Hachinski Ischemic Score
Uniﬁed Parkinson’s Disease Rating Scale
Clinical Dementia Rating
Neuropsychiatric Inventory Questionnaire
Geriatric Depression Scale
Functional Assessment Scale
Neurological Examination Findings

B9: Clinician Judgment of Symptoms
C2: Neuropsychological Battery Scores†
D1: Clinician Diagnosis

D2: Clinician-assessed Medical Conditions

Major Changes From Version 2 to Version 3
No major changes to form
No major changes to form
Added questions on: (1) family history of AD and FTLD mutations; (2) diagnosis
and age of onset for family members reported as having cognitive impairment
No major changes to form
Added questions on: (1) TBI without loss of consciousness and repeated TBI;
(2) sleep disorders (eg, sleep apnea); (3) psychiatric conditions (eg, PTSD,
anxiety); (4) alcohol use/frequency; and (5) medical conditions (eg, diabetes type,
arthritis.) Form is no longer completed at follow-up in lieu of Form D2
No major changes to form
Removed altogether (ie, to streamline the UDS)
Removed altogether (ie, to streamline the UDS)
No major changes to form
No major changes to form
No major changes to form
No major changes to form
Newly added form assessing neurological ﬁndings supportive of clinical diagnoses
(eg, eye movements consistent with PSP)
Added questions on: (1) ages of onset of behavioral and motor symptoms;
(2) changes in motor function consisting with ALS
Replaced proprietary tests (MMSE, Logical Memory Immediate and Delayed,
BNT, Digit Symbol) with nonproprietary tests: MoCA, Craft Story Immediate
and Delayed, Number Span Forward and Backward, MINT
Added questions and/or updated diagnostic criteria related to: (1) all-cause
dementia; (2) dementia syndromes (eg, PPA, bvFTD, DLB); (3) etiologic
diagnoses (eg, AD, FTLD, VBI, TBI); (4) biomarker and imaging ﬁndings;
(5) presence of AD and FTLD mutations
Newly added form assessing clinician-conﬁrmed medical conditions (eg, diabetes)

*Self-participant and co-participant reported.
†All newly enrolled participants must use Form C2 at their Initial Visit; however, participants originally enrolled using earlier UDS versions can continue
using Form C1 neuropsychological battery during follow-up.
AD indicates Alzheimer disease; ALS, amyotrophic lateral sclerosis; BNT, Boston Naming Test; bvFTD, behavioral variant frontotemporal dementia; DLB,
dementia with Lewy bodies; FTLD, frontotemporal lobar degeneration; MINT, Multilingual Naming Test; MMSE, Mini Mental State Exam; MoCA, Montreal
Cognitive Assessment; PPA, Primary Progressive Aphasia; PSP, progressive supranuclear palsy; PTSD, posttraumatic stress disorder; TBI, traumatic brain
injury; VBI, vascular brain injury.

medical conditions (Form D2) forms. Of note, the UPDRS
was incorporated into a module that assesses Lewy body
disorders (LBD module), which ADCs implemented in
August, 2017.
The Clinical Diagnosis Form D1 was updated to not
only adapt to the 2011 National Institute on AgingAlzheimer’s Association (NIA-AA) criteria for AD that
incorporated biomarkers [preclinical AD,5 mild cognitive
impairment due to AD (MCI-AD),6 and AD dementia7],
but also to the latest diagnostic criteria for conditions such
as frontotemporal degeneration (eg, behavioral variant
frontotemporal degeneration8 and primary progressive
aphasia9) and vascular brain injury. In addition, Version 3
of Form D1 incorporated new speciﬁc questions on AD and
FTLD mutations and on conditions including posterior
cortical atrophy (PCA), multiple system atrophy, human
immunodeﬁciency virus–associated neurocognitive disorder
(HAND), and psychiatric conditions including bipolar disorder and posttraumatic stress disorder. The Neurological
Exam Findings Form B8 was a new addition for Version 3,
aimed at capturing signs from the neurological exam consistent with speciﬁc neurodegenerative conditions such as
Parkinson disease (PD), progressive supranuclear palsy,
amyotrophic lateral sclerosis, and cerebrovascular disease.
Finally, Form D2 was added to gather data on medical
conditions that may confer risk for AD or dementia, such as
cardiovascular disease and diabetes, with the goal of
improving reliability and validity compared with the

participant/co-participant self-reported medical conditions
collected on Subject Health History Form A5.
In the months preceding implementation of UDS
Version 3, NACC staff developed the documentation necessary for ADCs to begin using the forms. This included
developing data element dictionaries10 (coding guides for all
variables), guidebooks11 (to guide clinicians on form completion), neuropsychological battery instructions12 for
clinicians, and data quality checks (to stop or ﬂag potentially erroneous data entry), among other documentation.
The data element dictionaries and accompanying documentation were provided to ADCs in advance so that they
could program their databases to submit the data to NACC
on the implementation date. In addition, NACC created
electronic forms for ease of data entry and modiﬁed the
UDS Oracle database and UDS data submission system to
allow for entry and storage of the Version 3 data. Before
implementation, ADC clinical leaders participated in a
webinar to learn about Version 3 changes and how to
complete the forms. UDS Version 3 was implemented by all
ADCs on March 15, 2015.
In October 2017, the Spanish translation of UDS Version 3 became available (Initial and Follow-up Visit Packet;
Neuropsychological Battery). Spanish translation involved
preliminary translation and content review by expert clinicians, and pilot testing at 3 US and 4 Latin American sites (see
the Acknowledgments section). Pilot testing revealed minimal
issues with the initial translation for the Montreal Cognitive
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Assessment (MoCA) (original Spanish version), Benson
Complex Figure (Copy and Delayed Recall), Number Span
Forward and Backward, Category Fluency (Animals and
Vegetables List Generation), and Trail Making Test Parts A
& B. However, adaption was required for the Craft Story
(Immediate and Delayed Recall), Verbal Fluency: Phonemic
Test (English: words beginning with F and L; Spanish: words
beginning with P and M), and the Multilingual Naming Test
(MINT). Once the Spanish translation became available to
ADCs, the Centers were asked to submit a Linguistic History
form to ascertain levels of acculturation for all UDS participants who identify as Hispanic or Latino. In addition to the
Spanish translation, UDS Version 3 has been translated into
Chinese, with plans for use in Alzheimer’s research centers
in China.

RESULTS
Table 1 outlines the major changes to the UDS with
Version 3 implementation. As of March 1, 2018, the UDS
(all versions) contains data on 37,568 participants followed
at 39 past and present ADCs. Longitudinal data ( ≥ 2 visits)
are available for 25,337 of the participants, with some participants having up to 13 UDS visits to date. Version 3
initial visit packets have been submitted on 4820 individuals.
Results reported below are based on data collected from
September 2005 through March 2018 using all 3 UDS
versions.
Approximately 4000 participants were younger than
60 years of age and ∼1000 were 90 years or older at their
initial visit (Table 2). Reﬂecting the shift in AD research
toward earlier detection, the age demographic shifted to
younger ages when comparing those enrolled using UDS
Version 3 to those enrolled using UDS Version 1 to 2 forms.
In addition, the number of individuals who were asymptomatic (global Clinical Dementia Rating = 0) increased from
37% among those enrolled using UDS Version 1 to 2 to 46%
among those enrolled using Version 3. Forty-one percent
had at least one apolipoprotein E (APOE) ε4 allele.
Although the large majority of the participants are white
(80%) and non-Hispanic (92%), 4726 participants are
African American, 896 are Asian, and 3079 are Hispanic.
MCI and dementia were clinically diagnosed in 7949 and
13,532 individuals at their initial visit, respectively (Table 3).
ADC clinicians are required to indicate the primary and
contributing etiologic diagnosis for MCI or dementia. AD
was the primary etiologic diagnosis for 40% of those with
MCI and 73% of those with dementia. Among the MCI
participants, primary etiologic diagnoses other than AD were
not as common (eg, 5% LBD, 5% vascular brain injury/
dementia, 4% depression), and in the remainder of dementia
participants, most had a diagnosis of LBD including PD (6%)
or FTLD with behavioral variant frontotemporal degeneration or primary progressive aphasia syndromes (12%).
Table 3 additionally provides the number of participants who
have at least 2 UDS visits (ie, longitudinal data) by their
primary etiologic diagnosis at their initial visit. For example,
among MCI participants with a primary etiologic diagnosis of
LBD at their initial visit, 126 completed 2 or 3 UDS visits and
97 completed at least 4 UDS visits.
A number of major additions and edits were made to
Clinician Diagnosis Form D1, including newly collected
information whether the subject had an AD (n = 14) or
FTLD (n = 27) mutation. Table 4 highlights the new
data elements collected with the implementation of UDS
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TABLE 2. Demographics and Clinical Characteristics of Uniform
Data Set Participants

Characteristic

Version 1-2
Initial Visit
Packet

Sample size (n)
32,748
Age at initial visit [n (%)]
< 60 y
3607 (11.0)
60-69 y
8577 (26.2)
70-79 y
12,028 (36.7)
80-89 y
7459 (22.8)
≥ 90 y
1077 (3.3)
Male [n (%)]
14,113 (43.1)
Education [n (%)]
< 12 y
2924 (9.0)
High school
6493 (20.0)
degree
Some/completed
23,099 (71.0)
college
Unknown
Race [n (%)]
White
26,090 (79.7)
Black/African
4096 (12.5)
American
American
182 (0.6)
Indian/Alaska
Native
Native
25 (0.1)
Hawaiian/
Paciﬁc
Islander
Asian
757 (2.3)
Multiracial
1065 (3.3)
Unknown
533 (1.6)
Hispanic ethnicity [n (%)]
Not Hispanic
30,112 (92.0)
Mexican/
834 (2.6)
Chicano/
MexicanAmerican
Puerto Rican
550 (1.7)
Cuban
241 (0.7)
Dominican
256 (0.8)
Central
148 (0.5)
American
South American
321 (1.0)
Other/unknown
150 (0.5)
Hispanic
origin
Ethnicity
136 (0.4)
unknown
No. UDS visits [n (%)]
1
8902 (27.2)
2-3
9779 (29.9)
4-5
6508 (19.9)
6-7
3757 (11.5)
8+
3802 (11.6)
≥ 1 APOE ε4
10,417 (40.6)
allele [n (%)]
Global CDR at initial visit
[n (%)]
0
12,253 (37.4)
0.5
11,839 (36.2)
1
5482 (16.7)
2
2046 (6.3)
3
1128 (3.4)

Version 3
All
Initial Visit Participants
Packet
Combined
4820
651
1588
1897
638
46
2061

37,568

(13.5)
4258 (11.3)
(33.0) 10,165 (27.1)
(39.4) 13,925 (37.1)
(13.2)
8097 (21.6)
(1.0)
1123 (3.0)
(42.8) 16,174 (43.1)

165 (3.5)
679 (14.3)

3089 (8.3)
7172 (19.3)

3905 (82.2) 27,004 (72.5)

3807 (79.0) 29,897 (79.6)
630 (13.1)
4726 (12.6)
51 (1.1)

233 (0.6)

2 (0.0)

27 (0.1)

139 (2.9)
106 (2.2)
85 (1.8)

896 (2.4)
1171 (3.1)
618 (1.7)

4377 (90.8) 34,489 (91.8)
86 (1.8)
920 (2.5)

77
95
29
34

(1.6)
(2.0)
(0.6)
(0.7)

627
336
285
182

(1.7)
(0.9)
(0.8)
(0.5)

79 (1.6)
24 (0.5)

400 (1.1)
174 (0.5)

19 (0.4)

155 (0.4)

3329 (69.1) 12,231 (32.6)
1489 (30.9) 11,268 (30.0)
2 (0.0)
6510 (17.3)
0
3757 (10.0)
0
3802 (10.1)
613 (39.4) 11,030 (40.6)

2203
1732
617
165
103

(45.7) 14,456 (38.5)
(35.9) 13,571 (36.1)
(12.8)
6099 (16.2)
(3.4)
2211 (5.9)
(2.1)
1231 (3.3)

APOE indicates apolipoprotein E; CDR, Clinical Dementia Rating;
UDS, Uniform Data Set.
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TABLE 3. Primary Etiologic Diagnoses for Mild Cognitive Impairment or Dementia at Initial Visit, by Number of Visits

MCI (N = 7949)
Primary Etiologic
Diagnosis*
AD
LBD including PD
FTLD
PSP
CBD
MND
Other (eg, bvFTD)
VBI/vascular dementia
Depression
Total including other
etiologies

Dementia (N = 13,532)

1 Visit
(n)

2-3 Visits
(n)

≥ 4 Visits
(n)

Total
[n (%)]

1 Visit
(n)

2-3 Visits
(n)

≥ 4 Visits
(n)

Total
[n (%)]

990
140

1023
126

1134
97

3147 (39.6)
363 (4.6)

3960
345

3313
316

2650
163

9923 (73.3)
824 (6.1)

10
15
1
65
151
142
2541

16
15
0
93
138
78
2518

4
5
0
67
107
87
2890

30
35
1
225
396
307
7949

77
88
9
600
126
14
5538

49
70
1
597
75
2
4581

12
23
0
408
54
5
3413

(0.4)
(0.4)
(0.0)
(2.8)
(5.0)
(3.9)
(100.0)

138
181
10
1605
255
21
13,532

(1.0)
(1.3)
(0.1)
(11.9)
(1.9)
(0.2)
(100.0)

*Including participants administered any version of the UDS (ie, Version 1, 2, or 3).
AD indicates Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia; CBD, corticobasal degeneration; col, column; FTLD, frontotemporal
lobar degeneration; LBD, Lewy body disease; MCI, mild cognitive impairment; MND, motor neuron disease; PD, Parkinson disease; PSP, progressive
supranuclear palsy.

TABLE 4. Highlights of Data Added to Assessment for Version 3,
By Form

Data From Initial Visit for
n = 4820 Participants
Form A3 (Subject Family History)
Family member(s) with known AD mutation
Family member(s) with known FTLD mutation
Form A5 (Subject Health History)
TBI without loss of consciousness
Repeated TBI
Form B8 (Neurological Exam Findings)
Parkinsonian signs
Neurological signs consistent with cerebrovascular
disease
Higher cortical visual problem suggesting PCA
Findings suggestive of PSP, CBS, or related
disorder
Findings suggestive of ALS
Normal-pressure hydrocephalus: gait apraxia
Form D1 (Clinician Diagnosis)
Participant has AD mutation
Participant has FTLD mutation
PCA syndrome
FTLD with motor neuron disease
Presumed FTLD subtype
Tauopathy
TDP-43 proteinopathy
Other/unknown subtype
Signiﬁcant vascular brain injury
Essential tremor
Symptoms consistent with chronic traumatic
encephalopathy
Posttraumatic stress disorder
Form D2 (Clinician-assessed Medical Conditions)
Cancer
Arthritis
Sleep apnea
Antibody-mediated encephalopathy

Presence
[n (%)]
27 (0.6)
51 (1.1)
320 (6.6)
222 (4.6)
471 (9.8)
143 (3.0)
57 (1.2)
134 (2.8)
27 (0.6)
8 (0.2)
14
27
42
16

(0.3)
(0.6)
(0.9)
(0.3)

81
75
160
305
70
17

(1.7)
(1.6)
(3.3)
(6.3)
(1.5)
(0.4)

32 (0.7)
689
2250
745
7

(14.3)
(46.7)
(15.5)
(0.2)

AD indicates Alzheimer’s disease; ALS, amyotrophic lateral sclerosis;
CBS, corticobasal syndrome; FTLD, frontotemporal lobar degeneration;
PCA, Posterior Cortical Atrophy; PSP, primary supranuclear palsy;
TBI, traumatic brain injury.

Version 3. Twenty-seven individuals reported having family
members with a known AD mutation (PS1, PS2, or APP),
and 51 reported family with an FTLD mutation (MAPT,
PGRN, C9ORF72, FUS).
With Version 3, additional details are collected on TBI,
including individuals with TBI without loss of consciousness
(n = 320) and repeated TBI (n = 222) (Table 4). Detailed
neurological examination ﬁndings on the new Form B8
included parkinsonian signs (n = 471 participants) and
higher cortical visual problem suggesting PCA (n = 143).
A number of diagnoses not previously collected were also
added to Form D1, including PCA syndrome (n = 42 participants), FTLD with motor neuron disease (n = 16),
essential tremor (n = 70), symptoms consistent with chronic
traumatic encephalopathy (n = 17), and posttraumatic stress
disorder (n = 32). Finally, the new Clinician-assessed Medical Conditions Form D2 records data on a variety of
clinician-endorsed conditions, including cancer (n = 689
participants), arthritis (n = 2250), and sleep apnea (n = 745).
A substantial number of UDS participants have additional data sets that are also available at NACC. Neuropathology (NP) data13 are available for 5135 UDS
participants who have died and consented to autopsy
(Table 5). Data from the FTLD module (symptoms, diagnoses, imaging evidence, and neuropsychological test
ﬁndings speciﬁc to FTLD) are available for 1324 UDS
participants. MRI are available to download for 4616 participants. Among individuals with MRI, 1317 have measures of regional brain volumes (eg, hippocampal volume).
Amyloid positron emission tomography (PET) is available
for download for 370 participants and cerebrospinal ﬂuid
(CSF) biomarker data for 1100 participants. In addition,
genetic data are available for 13,180 UDS participants by
request from the Alzheimer’s Disease Genetics Consortium
(ADGC), and deoxyribonucleic acid (DNA) samples are
available for 23,381 by request from the National Cell
Repository for Alzheimer’s Disease (NCRAD).
Table 5 provides ﬁner grained details on the number of
participants who have these additional data by their primary
etiologic diagnosis. For instance, the large majority
of individuals (81%) with amyloid PETs available for
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TABLE 5. Additional Data Available on Uniform Data Set Participants by Primary Etiologic Diagnosis at Most Recent Visit

Additional Data Available (n)
MRI
Calculated
Volumes

FTLD
Neuropathology Module MRI
Normal cognition
Impaired, not MCI
MCI, etiologic dx
AD
LBD including PD
FTLD
PSP
CBD
MND
Other (eg, bvFTD)
VBI/vascular dementia
Total MCI
Dementia, etiologic dx
AD
LBD including PD
FTLD
PSP
CBD
MND
Other (eg, bvFTD)
VBI/vascular dementia
Total dementia
Total participants

Amyloid
CSF
Genetic Data
PET
Biomarker
at ADGC

DNA Sample
at NCRAD

553
73

347
33

1978
129

689
22

275
25

394
38

6209
248

8941
981

210
33

37
10

467
35

109
8

24
1

76
19

698
35

2157
179

4
7
0
10
43
427

5
12
2
58
4
159

0
2
0
13
95
806

0
1
0
2
40
209

0
0
0
0
3
50

0
1
0
5
4
160

0
0
0
6
93
1083

14
19
2
81
287
3780

2721
353

150
8

1353
114

347
11

17
0

381
34

5172
167

7249
551

86
91
5
550
93
4082
5135

56
44
14
479
3
785
1324

13
10
1
98
42
1703
4616

1
0
0
6
16
397
1317

0
0
0
0
0
20
370

4
7
1
29
8
508
1100

7
30
1
98
116
5640
13180

115
151
16
1074
225
9679
23381

AD indicates Alzheimer disease; ADGC, Alzheimer’s Disease Genetics Consortium; bvFTD, behavioral variant frontotemporal dementia;
CBD, corticobasal degeneration; CSF, cerebrospinal ﬂuid; dx, diagnosis; FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease; MCI, mild
cognitive impairment; MND, motor neuron disease; MRI, magnetic resonance images; NCRAD, National Cell Repository for Alzheimer’s Disease; PD,
Parkinson disease; PET, positron emission tomography; PSP, progressive supranuclear palsy; VBI, vascular brain injury.

download had a clinical diagnosis of normal cognition or
impaired not MCI (some impairment that does not meet
MCI criteria) at their most recent visit, and 166 MCI participants and 540 dementia participants with a diagnosis of
LBD (including PD) have DNA samples stored at NCRAD.

DISCUSSION
After considerable deliberation, compromise, and collaboration, the CTF, the ADCs, and NACC implemented
UDS Version 3 in March 2015. There was a relatively
lengthy period of evaluation, discussion, and negotiation
amongst the expert ADC clinicians who made up the regular CTF and those who were part of the associated ad hoc
subcommittees as well as other ADC clinicians. The CTF
considered how to incorporate new developments in the
ﬁeld, while preserving longitudinal continuity with the
> 10 years of data collected in the prior UDS versions.
Deletions, updates, and additions to the UDS needed to
balance the needs of ∼30 Centers that each have their distinct research priorities and different participant characteristics (eg, age, primary diagnosis). Clinician opinion differs
regarding the most important forms and questions to collect
in the UDS within and across multiple ADCs. The CTF
weighed the need to assess key clinical characteristics for the
increasing number of neurodegenerative diseases studied
within the ADC program against the need to keep the UDS
as parsimonious as possible, being mindful of the clinicians’,
research staffs’, and participants’ time. The resulting UDS
Version 3, as in the prior UDS versions, demonstrates the
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ability of researchers from numerous institutions to collaborate and implement a standardized data collection instrument for over a decade.
An important contribution of the UDS is that it provides
standardized instruments that can be supplemented with
additional modules such as the FTLD and LBD modules,
which were implemented by ADCs in January 2012 and
August 2017, respectively. ADCs voluntarily submit the
modules for individuals suspected to have FTLD or LBD, but
additionally for individuals with AD or controls, which aids in
determining the discriminative capabilities of the module
instruments. To date, 1324 participants have completed the
FTLD module, 464 of which have longitudinal FTLD module visits. As of March 2018, the LBD module data have not
accumulated in sufﬁcient numbers to provide to researchers,
but the initial visit forms and documentation for the LBD and
FTLD modules are viewable on the NACC website (www.alz.
washington.edu/WEB/dataforms_main.html). In addition,
researchers outside of the ADCs may request permission to
use the UDS or associated modules. In the future, additional
modules can be added to the UDS to collect more detailed
data on a speciﬁc subpopulation or neurodegenerative disease
(eg, preclinical disease).
The UDS serves as a foundation to integrate not only
standardized clinical assessments of participants with
NACC’s NP data set, but also to incorporate novel MRI,
PET, and CSF biomarker data with these important clinical
characteristics. The NACC database is adaptable and thus
capable of receiving supplemental data such as the imaging
and ﬂuid biomarker data that complement the UDS and
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also reﬂect the trending research priorities of the ADCs.
Along with the data that are either readily available at
NACC or that can be linked to the UDS via the ADGC (eg,
genome-wide association study) or NCRAD (eg, DNA
samples), researchers can supplement the UDS data through
a special request to one or more ADCs to obtain additional
data not available at NACC (requests for UDS data, supplemental data and modules, and special requests for
external data/specimens can be initiated at http://www.alz.
washington.edu). This process of requesting external data
from ADCs is initially coordinated by NACC. As an
example, one such study gained approval from 15 ADCs to
survey participants of 4 different racial/ethnic groups about
their willingness to commit to post mortem brain
donation.14 Researchers also work with NACC to determine
samples of brain tissue that may be available for sharing
from one or more ADCs. An example is a published study
that combined existing NP data at NACC with supplemental data on number of microinfarcts through abstraction
of University of Washington and Oregon Health and Science University ADC records to examine the associations
between mixed pathologies and domain-speciﬁc cognitive
decline.15
The growing depth and breadth of the UDS and of the
additional data that can be linked to the UDS has resulted
in an ever increasing number of published manuscripts using
the NACC data (n = 481 as of March 16, 2018) (viewable
under “Publications and Productivity” link at www.alz.
washington.edu). Early papers using the UDS were limited
in terms of sample size and tended to focus on descriptions
of the UDS sample or various methodological issues. In
contrast, papers published using the UDS data in the ﬁrst
quarter of 201816–32 investigated a wide range of topics, such
as inappropriate medication use among those with incident
dementia,27 TBI history and early age of onset in autopsyconﬁrmed AD,28 big data approaches to preclinical trial
enrichment,24 and predicting sex differences in MCI and AD
using data on white matter hyperintensities and hippocampal volume.17 Thus, the demonstrated increase in publications using UDS data suggests that the UDS revisions
described in this article have tailored the standardized data
collection to measures that are more useful for researchers.
The volume of the published articles and abstracts
using the UDS and the continually increasing diversity of
topics are evidence of the value of the data to junior and
seasoned researchers alike. The strengths of the UDS
include not only the types of data that can be linked to it,
but its longitudinal nature and the availability of sufﬁcient
sample sizes to study rarer conditions or special populations
not otherwise feasible. For instance, UDS data provide
opportunities for ﬁner grain analyses focused on Hispanics/
Latinos of speciﬁc origins. In addition, the ability to merge
clinical data with NP data is critical, as NP remains the gold
standard for neurodegenerative diseases such as AD.
Although the UDS exhibits a number of strengths
desirable to researchers, anyone using the data must
acknowledge its weaknesses when conducting a study or
interpreting ﬁndings. Recruitment methods for the UDS
sample have varied between ADCs and within each ADC
over time, and are often based on convenience samples such as
recruitment through clinics or participant referrals. The beneﬁt of this approach is that ADCs are able to enrich their
samples with individuals who have or are more likely to
develop neurodegenerative disease. In addition, as mentioned
above, ADCs have distinct research priorities and sample

National Alzheimer’s Coordinating Center

characteristics. The differences in recruitment and sample
characteristics across the ADCs provide a heterogenous and
diverse group with which to study, but this also means that the
sample is not population-based and thus may not truly reﬂect
local ADC communities or the larger US population. Another
limitation is that the UDS Version 3 neuropsychological
battery is missing a verbal list learning task such as the Rey
Auditory Verbal Learning Test. The Neuropsychology Work
Group decided against adding a verbal list learning task
because the options were mostly proprietary (a major goal in
developing the UDS 3 battery was to be nonproprietary), and
because of the wide range of verbal list instruments used
across ADCs, which would have created burden on the ADCs
that have long established cohorts using an instrument not
chosen for UDS Version 3. Also, the UDS instruments have
changed over time, which can present a challenge to investigators wishing to use the longitudinal data (ie, neuropsychological test battery changed from UDS Version 2 to 3)
or wishing to use the largest possible samples sizes (deﬁnition
of TBI history changed from UDS Version 2 to 3). NACC
developed the researchers data dictionary (RDD-UDS33) to
harmonize data across the UDS versions, whenever possible,
to try to minimize this issue and ensure researchers are aware
of important UDS version changes. In addition, NACC
research staff are available to consult with researchers who
have questions about version changes, or other details about
the UDS data.
UDS Version 3 demonstrates a number of advantages
and improvements over the prior versions, collecting new and
pertinent data in line with the evolving research interests at the
ADCs. UDS Version 3 was developed in a manner that allows
it to be combined with the previous versions, so that the
longitudinal nature of the UDS and the legacy data remain
accessible to researchers. A distinct advantage of UDS Version 3 is that it is nonproprietary. With permission, Version 3
can be used in other studies, allowing for a common method
of assessing cognition and clinical characteristics among those
with normal cognition and various neurological diseases and
also providing the ability to compare ﬁndings across various
studies and cohorts. Examples of research studies that are
using UDS forms include the Dominantly Inherited Alzheimer Network (DIAN), the Advancing Research and
Treatment for Frontotemporal Lobar Degeneration Consortium (ARTFL) and the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). In
addition, the UDS data can be combined with valuable data
internal and external to NACC, including imaging, CSF
biomarker, and genetic data. Since its inception in 2005, the
UDS has highlighted the possibility for numerous research
institutions with sometimes disparate priorities to collaborate
with each other to produce and use standardized data collection instruments. Version 3 was no exception, and with its
implementation, it provides researchers a unique, valuable
resource to facilitate acceleration of novel AD and related
disorders research.
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